Product Description
a CAR-T adaptor molecule (CAM)-based therapy that uses a bispecific small-molecule ligand EC17, fluorescein isothiocyanate (FITC) conjugated with folic acid, to redirect FITC-specific CAR-T cells against folate receptor (FR)-positive tumors. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433934/)
Mechanisms of Action: FRa Contrast Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Ovarian Cancer|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma
Phase 1: Renal Cell Carcinoma|Breast Cancer|Hyperparathyroidism, Primary|Ovarian Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02000778 |
818533 [UPenn IRB Protocol #] | P1 |
Completed |
Ovarian Cancer |
2014-11-12 |
2024-06-26 |
Primary Endpoints|Treatments |
|
NCT01994369 |
EC17 | P1 |
Completed |
Breast Cancer |
2014-11-01 |
2019-03-20 |
Treatments |
|
NCT01996072 |
818060 [UPenn IRB Protocol] | P1 |
Completed |
Hyperparathyroidism, Primary |
2014-09-01 |
2019-03-20 |
Treatments |
|
NCT01778933 |
EC17 | P1 |
Completed |
Renal Cell Carcinoma |
2014-09-01 |
2019-03-19 |
||
2013-004089-33 |
2013-004089-33 | P2 |
Completed |
Ovarian Cancer|Non-Small-Cell Lung Cancer |
2015-04-01 |
2022-03-13 |
Treatments |
|
NCT00485563 |
EC-FI-004 | P2 |
Terminated |
Renal Cell Carcinoma |
2008-08-01 |
2025-08-27 |
Primary Endpoints|Treatments |